US court tosses out FTC's challenge to alleged "pay-for-delay" Androgel settlement
This article was originally published in Scrip
A US federal judge has thrown out a Federal Trade Commission antitrust lawsuit alleging that Abbott Laboratories' Solvay unit conspired with generic drug makers to delay competition for its testosterone supplement Androgel. Judge Thomas Thrash of the US District Court for the Northern District of Georgia joined other federal courts in upholding drug companies' right to make so-called "reverse payment", or what the FTC now prefers to call "pay-for-delay", agreements. The judge also dismissed related antitrust claims brought by private plaintiffs who paid for Androgel.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.